Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Per Byström
Observed names:
P Byström,
P. Bystrom,
P. Byström,
Per Byström
Institution:
Novartis (Sweden)
Observed institutions:
Uppsala University,
Karolinska University Hospital,
University of Oslo,
Lund University,
Stavanger University Hospital,
Karolinska Institutet,
St Olav's University Hospital,
Novartis (Sweden)
show all 8
OpenAlex ID:
A5113614070
Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer
2008
·
Morten Brændengen
, Kjell M. Tveit
, et al.
·
Journal of Clinical Oncology
·
482
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
2010
·
B Glimelius
, H Garmo
, et al.
·
The Pharmacogenomics Journal
·
122
PDF
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy
2011
·
C. Suzuki
, L. Blomqvist
, et al.
·
Annals of Oncology
·
110
PDF
TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid
2007
·
Nanna M. Sørensen
, Per Byström
, et al.
·
Clinical Cancer Research
·
78
PDF
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer
2009
·
P. Byström
, Å. Berglund
, et al.
·
Annals of Oncology
·
72
PDF
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
2008
·
B. Glimelius
, H. Sørbye
, et al.
·
Annals of Oncology
·
47
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
2016
·
A. Maleka
, G. Åström
, et al.
·
BMC Cancer
·
42
PDF
Evaluation of predictive markers for patients with advanced colorectal cancer
2012
·
Per Byström
, Åke Berglund
, et al.
·
Acta Oncologica
·
40
PDF
Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma
2008
·
Pehr A. Lind
, Bengt Isaksson
, et al.
·
Acta Oncologica
·
35
PDF
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer
2009
·
B. Glimelius
, M. Lahn
, et al.
·
Annals of Oncology
·
25
High Plasma TIMP-1 and Serum CEA Levels during Combination Chemotherapy for Metastatic Colorectal Cancer Are Significantly Associated with Poor Outcome
2010
·
Bahir Aldulaymi
, Per Byström
, et al.
·
Oncology
·
23
Serum vitamin B12 and folate status among patients with chemotherapy treatment for advanced colorectal cancer
2009
·
Per Byström
, Karin Björkegren
, et al.
·
Upsala Journal of Medical Sciences
·
21
PDF
Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study
2008
·
Adalsteinn Gunnlaugsson
, Harald Anderson
, et al.
·
European Journal of Cancer
·
21
Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer
2004
·
P. Byström
, J.-E Frödin
, et al.
·
Radiotherapy and Oncology
·
8
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer
2009
·
Åke Berglund
, Per Byström
, et al.
·
Medical Oncology
·
7
Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study
2009
·
B. Glimelius
, K.L. Spindler
, et al.
·
Annals of Oncology
·
6
Health-related quality of life in patients with metastatic colorectal cancer receiving palliative combination chemotherapy
2012
·
Per Byström
, Birgitta Johansson
, et al.
·
3
Initial change in tumor size as an imaging surrogate of outcomes in patients with metastatic colorectal cancer (mCRC) treated with first-line irinotecan and 5-FU combination chemotherapy.
2011
·
C. Suzuki
, L. Blomqvist
, et al.
·
Journal of Clinical Oncology
Colorectal cancer treatment and early response evaluation, how do we best evaluate treatment response?
2010
·
Per Byström
·
Figshare
Reply to FDG–PET: for early prediction of response to the first-line chemotherapy in metastatic colorectal cancer?
2009
·
P. Byström
, B. Glimelius
·
Annals of Oncology
Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma
2007
·
P. A. Lind
, B. Isaksson
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
22
Citation count:
1,142
H-index:
13
I10-index:
13
Year
Topic
Type